Serum endothelial monocyte-activating polypeptide-II: A novel biomarker in patients with non-small-cell lung cancer

ŞEN E., Ulger F., EROL S., Akar N., Gonullu U.

CLINICAL LUNG CANCER, cilt.9, sa.3, ss.166-170, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 3
  • Basım Tarihi: 2008
  • Doi Numarası: 10.3816/clc.2008.n.025
  • Dergi Adı: CLINICAL LUNG CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.166-170
  • Anahtar Kelimeler: Antiangiogenic factors, clinicopathologic, features, thrombospondin, EMAP-II, TUMOR-DERIVED CYTOKINE, EMAP-II, APOPTOSIS, ANGIOGENESIS, EXPRESSION, ENDOSTATIN, PROGNOSIS, THERAPY, RELEASE, GROWTH
  • Ankara Üniversitesi Adresli: Evet

Özet

BACKGROUND: Endothelial monocyte-activating polypeptide-II (EMAP-II) is a proinflammatory cytokine with antiangiogenic properties. Serum EMAP-II levels have not been investigated previously in non-small-cell lung cancer (NSCLC). The aim of this study was to examine the relationship between serum EMAP-II levels and clinicopathollogic features, including prognosis, in patients with NSCLC. PATIENTS AND METHODS: We measured serum EMAP-II levels in 30 healthy control subjects and 48 patients with untreated NSCLC by enzyme linked-immunosorbent assay. RESULTS: Patients with NSCLC had significantly higher serum EMAP-II levels than did the control group (492 pg/mL +/- 1126 pg/mL vs. 266 pg/mL +/- 1013 pg/mL; P =.015). No significant association was found between serum EMAP-II levels and various clinicopathologic features (age, smoking history, performance status, histopathology, tumor stage, lymph node stage, or distant metastasis). Median survival time was 10.13 months (range, 2-53.8 months). The high-EMAP-II (>= 100 pg/mL) group had a shorter survival compared with the low-EMAP-II (< 100 pg/mL) group (P =.023), and the serum EMAP-II level was still an important predictor of survival in a multivariate analysis, along with disease stage. CONCLUSION: Our results showed that serum EMAP-II levels are significantly higher in patients with NSCLC than in healthy subjects and suggest it is of potential prognostic value.